Insmed Incorporated to Present at Two Investor Conferences in September.
PorAinvest
jueves, 21 de agosto de 2025, 7:37 am ET1 min de lectura
INSM--
Insmed Incorporated is dedicated to delivering first- and best-in-class therapies to transform the lives of patients facing serious diseases. The company's portfolio includes approved and mid- to late-stage investigational medicines, as well as cutting-edge drug discovery focused on serving patient communities with the greatest need. Insmed's most advanced programs are in pulmonary and inflammatory conditions, including two approved therapies for chronic, debilitating lung diseases [2].
The company's early-stage programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Insmed is headquartered in Bridgewater, New Jersey, with offices and research locations throughout the United States, Europe, and Japan [3].
Investors and media interested in attending the presentations can visit the company's investor relations section on its website for more information. The webcasts will be archived for 30 days following the conclusion of the live events.
References:
[1] https://www.prnewswire.com/news-releases/insmed-to-present-at-september-investor-conferences-302535055.html
[2] https://finance.yahoo.com/news/insmed-present-september-investor-conferences-110000193.html
[3] https://www.marketscreener.com/news/insmed-to-present-at-september-investor-conferences-ce7c51d3df88ff27
Insmed Incorporated announced that management will present at the Wells Fargo 2025 Healthcare Conference in Boston on September 5, 2025, and the Morgan Stanley 23rd Annual Global Healthcare Conference in New York on September 9, 2025. The events will be webcast live and available on the company's website. Insmed Incorporated is a biopharmaceutical company focused on delivering therapies for serious diseases.
Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company, has announced that its management will present at two prominent investor conferences in September. The company will participate in the Wells Fargo 2025 Healthcare Conference in Boston on Friday, September 5, 2025, at 8:00 a.m. ET, and the Morgan Stanley 23rd Annual Global Healthcare Conference in New York on Tuesday, September 9, 2025, at 4:50 p.m. ET. Both events will be webcast live and accessible via the company's investor relations section on its website [1].Insmed Incorporated is dedicated to delivering first- and best-in-class therapies to transform the lives of patients facing serious diseases. The company's portfolio includes approved and mid- to late-stage investigational medicines, as well as cutting-edge drug discovery focused on serving patient communities with the greatest need. Insmed's most advanced programs are in pulmonary and inflammatory conditions, including two approved therapies for chronic, debilitating lung diseases [2].
The company's early-stage programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Insmed is headquartered in Bridgewater, New Jersey, with offices and research locations throughout the United States, Europe, and Japan [3].
Investors and media interested in attending the presentations can visit the company's investor relations section on its website for more information. The webcasts will be archived for 30 days following the conclusion of the live events.
References:
[1] https://www.prnewswire.com/news-releases/insmed-to-present-at-september-investor-conferences-302535055.html
[2] https://finance.yahoo.com/news/insmed-present-september-investor-conferences-110000193.html
[3] https://www.marketscreener.com/news/insmed-to-present-at-september-investor-conferences-ce7c51d3df88ff27
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios